Where does Odyssey Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Odyssey Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	Q1 '26
Net income	-$38.26M+0.5%
Depreciation and amortization	$1.17M-9.9%
Stock-based compensation	$2.59M-13.4%
Gain (loss) on sale of assets	$33K+107%
Change in accounts payable	$484K-32.1%
Change in accrued liabilities	-$4.77M-34.6%
Change in other assets	$1.69M-16.0%
Change in operating lease liabilities	-$1.23M-15.0%
Net cash from operating activities	-$41.04M-6.3%
Capital expenditures	$148K-84.0%
Proceeds from maturities/sales of investments	$34.95M-0.1%
Proceeds from sale of property, plant and equipment	$0-100%
Net cash from investing activities	$34.8M+2.0%
Proceeds from issuance of common stock	$651K+177%
Payments for finance leases	$24K-31.4%
Payment of debt issuance costs	$143K—
Net cash from financing activities	$484K+142%
Effect of exchange rate changes on cash	$24K-65.2%
Net increase (decrease) in cash	-$5.73M-35.5%
Interest paid	$10K+400%
Income taxes paid	$30K-25.0%
Change In Fair Value Of Contingent Consideration And Warrant Liability	$109K+102%
Accounts payable	$484K-32.1%
Operating lease liabilities	-$1.23M-15.0%
Other current liabilities	-$4.77M-34.6%
Increase (Decrease) in Prepaid Expense and Other Assets	-$3K+99.5%
Investment Income, Amortization of Discount	$296K-40.9%
Non Cash Rent Expense	$879K-14.2%
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale	$34.95M-0.1%
Proceeds from disposals of property, plant and equipment	$0-100%
Finance Lease, Principal Payments	$24K-31.4%
Payments Of Debt Issuance Costs	$143K—
Accrued payables for capital expenditures	$0—
Deferred Offering Costs Included In Accounts Payable And Accrued Expenses And Other Current Liabilities	$1.6M-71.8%
Finance Lease Right Of Use Asset Amortization	$0-100%
Increase Decrease In Operating Lease Liability	-$1.23M-15.0%
Leased assets obtained in exchange for finance lease liabilities	$278K—
Free cash flow	-$41.18M-4.1%
Free cash flow	-$41.18M-4.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Odyssey Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Odyssey Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.